Articles published in Journal of Neurology & Neurophysiology have been cited by esteemed scholars and scientists all around the world. Journal of Neurology & Neurophysiology has got h-index 17, which means every article in Journal of Neurology & Neurophysiology has got 17 average citations.
Following are the list of articles that have cited the articles published in Journal of Neurology & Neurophysiology.
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
Year wise published articles |
60 | 60 | 24 | 25 | 26 |
Year wise citations received |
200 | 239 | 223 | 219 | 187 |
| Journal total citations count | 1487 |
| Journal Impact Factor | 3.20 |
| Journal 5 years Impact Factor | 4.17 |
| Journal CiteScore | 4.13 |
| Journal h-index | 17 |
| Journal Impact Factor 2020 formula |
| IF= Citations(y)/{Publications(y-1)+ Publications(y-2)} Y= Year |
| Journal 5-year Impact Factor 2020 formula |
| Citations(2016 + 2017 + 2018 + 2019 + 2020)/ {Published articles(2016 + 2017 + 2018 + 2019 + 2020)} |
| Journal CiteScore |
| CiteScorey = Citationsy + Citationsy-1 + Citationsy-2 + Citations y-3 / Published articlesy + Published articlesy-1 + Published articlesy-2 + Published articles y-3 |
Pantazou, V., Du Pasquier, R., Pot, C., Le Goff, G., & Théaudin, M. (2021). Is disease activity prior to fingolimod initiation predictive of response? Fingolimod as a “common” first line treatment. Revue Neurologique. |
|
Sufianova, G.Z. PECULIARITIES OF THE NEUROPROTECTIVE ACTION OF CYTICOLINE IN EXPERIMENTAL BRAIN ISCHEMIA. |
|
Comi, G., Dalla Costa, G., & Moiola, L. (2021). Newly approved agents for relapsing remitting multiple sclerosis: how real-world evidence compares with randomized clinical trials?. Expert review of neurotherapeutics, 21(1), 21-34. |
|
Kumar, A., & Nagar, M. Research and Reviews: Journal of Medical and Health Sciences. differentiation, 10, 11. |
|
Zivadinov, R., Khan, N., Korn, J. R., Lathi, E., Silversteen, J., Calkwood, J., ... & Weinstock-Guttman, B. (2018). No evidence of disease activity in patients receiving fingolimod at private or academic centers in clinical practice: a retrospective analysis of the multiple sclerosis, clinical, and magnetic resonance imaging outcomes in the USA (MS-MRIUS) study. Current medical research and opinion, 34(8), 1431-1440. |
|
Kanyal, N. (2015). The science of ischemic stroke: pathophysiology & pharmacological treatment. International Journal of Pharma Research & Review, 4(10), 65-84. |
|
Tichá, V., Kodým, R., Po?íková, Z., & Kadlecová, P. (2017). Real-world outcomes in fingolimod-treated patients with multiple sclerosis in the Czech Republic: results from the 12-month GOLEMS study. Clinical drug investigation, 37(2), 175-186. |
|
Ciancarelli, I., De Amicis, D., Di Massimo, C., Pistarini, C., & Giuliana Tozzi Ciancarelli, M. (2016). Mean platelet volume during ischemic stroke is a potential pro-inflammatory biomarker in the acute phase and during neurorehabilitation not directly linked to clinical outcome. Current neurovascular research, 13(3), 177-183. |
|
Lanzillo, R., Carotenuto, A., Moccia, M., Saccà, F., Russo, C. V., Massarelli, M., ... & Brescia Morra, V. (2017). A longitudinal real?life comparison study of natalizumab and fingolimod. Acta Neurologica Scandinavica, 136(3), 217-222. |
|
Ojo, O. B., Amoo, Z. A., Saliu, I. O., Olaleye, M. T., Farombi, E. O., & Akinmoladun, A. C. (2019). Neurotherapeutic potential of kolaviron on neurotransmitter dysregulation, excitotoxicity, mitochondrial electron transport chain dysfunction and redox imbalance in 2-VO brain ischemia/reperfusion injury. Biomedicine & Pharmacotherapy, 111, 859-872. |
|
Weinstock-Guttman, B., Medin, J., Khan, N., Korn, J. R., Lathi, E., Silversteen, J., ... & Zivadinov, R. (2018). Assessing ‘no evidence of disease activity’status in patients with relapsing-remitting multiple sclerosis receiving fingolimod in routine clinical practice: a retrospective analysis of the Multiple Sclerosis Clinical and Magnetic Resonance Imaging Outcomes in the USA (MS-MRIUS) study. CNS drugs, 32(1), 75-84. |
|
Zhang, X., Xu, Z., Lin, F., Wang, F., Ye, D., & Huang, Y. (2016). Increased oxidative DNA damage in placenta contributes to cadmium-induced preeclamptic conditions in rat. Biological trace element research, 170(1), 119-127. |
|
Ziemssen, T., Medin, J., Couto, C. A. M., & Mitchell, C. R. (2017). Multiple sclerosis in the real world: a systematic review of fingolimod as a case study. Autoimmunity reviews, 16(4), 355-376. |
|
Ciancarelli, I., Di Massimo, C., De Amicis, D., Pistarini, C., & Giuliana Tozzi Ciancarelli, M. (2015). Uric acid and Cu/Zn superoxide dismutase: potential strategies and biomarkers in functional recovery of post-acute ischemic stroke patients after intensive neurorehabilitation. Current neurovascular research, 12(2), 120-127. |
|
Cicho?, N., Bijak, M., Miller, E., & Saluk, J. (2017). Extremely low frequency electromagnetic field (ELF?EMF) reduces oxidative stress and improves functional and psychological status in ischemic stroke patients. Bioelectromagnetics, 38(5), 386-396. |
|
Tanovska, N., Novotni, G., Sazdova-Burneska, S., Kuzmanovski, I., Boshkovski, B., Kondov, G., ... & Isjanovska, R. (2018). Myasthenia gravis and associated diseases. Open Access Maced J Med Sci. |
|
Verwijst, J., Westerberg, E., & Punga, A. R. (2021). Cancer in myasthenia gravis subtypes in relation to immunosuppressive treatment and acetylcholine receptor antibodies: A Swedish nationwide register study. European Journal of Neurology, 28(5), 1706-1715. |
|
Chou, C. C., Huang, M. H., Lan, W. C., Kong, S. S., Kuo, C. F., & Chou, I. J. (2020). Prevalence and risk of thyroid diseases in myasthenia gravis. Acta Neurologica Scandinavica, 142(3), 239-247. |
|
Tripathi, S. Research and Reviews: Journal of Pharmaceutics and Nanotechnology. Nanotechnology, 7, 10. |
|
Dube, M., Sodani, A., & Chouksey, D. (2017). Outcome of Myasthenia gravis treated with high-dose prednisolone and azathioprine: A single centre ambispective study from India. Acta Neurol Taiwan, 26, 106-119. |
|
